Enrich Therapeutics develops novel single cell isolation technology to enhance global biomedical research at true single cell level!

Different from all existing fluidic and droplet-based technologies, our platform is a game-changing innovation and can work on adherent cells and many non-ideal cell samples robustly with high viability.

Enrich Therapeutics' static cell capture technology enables clone isolation under the desired micro-environment with real-time monitoring. Enrich technology is making extensive impact in fields of basic biology, CAR-T, antibody, tumor genetics, etc., and is committed to isolating single clones from any physiologically relevant scenario.

Market Size
Massive addressable cell isolation market with Enrich proprietary technology